278
Views
11
CrossRef citations to date
0
Altmetric
Rapid Communication

UVA radiation augments cytotoxic activity of psoralens in melanoma cells

, , , , , , , & show all
Pages 734-739 | Received 06 Nov 2016, Accepted 12 Feb 2017, Published online: 13 Mar 2017
 

Abstract

Purpose: Melanoma is an aggressive form of skin cancer. The aim of the study was to evaluate the influence of UVA radiation and psoralens: 5-methoxypsoralen (5-MOP) or 8-methoxypsoralen (8-MOP) on melanoma cells viability.

Materials and methods: The amelanotic C32 and melanotic COLO829 human melanoma cell lines were exposed to increasing concentrations of psoralens (0.1–100 μM) in the presence or absence of UVA radiation. Cell viability was evaluated by the WST-1 assay.

Results: We demonstrated that 8-MOP, in contrast to 5-MOP, has no cytotoxic effect on both melanoma cell lines. Simultaneous exposure of cells to 8-MOP and UVA radiation caused significant cytotoxic response in C32 cells where the EC50 value was estimated to be 131.0 μM (UVA dose: 1.3 J/cm2) and 105.3 μM (UVA dose: 2.6 J/cm2). The cytotoxicity of 5-MOP on both C32 and COLO829 cells was significantly augmented by UVA radiation – the EC50 was estimated to be 22.7 or 7.9 μM (UVA dose: 1.3 J/cm2) and 24.2 or 7.0 μM (UVA dose: 2.6 J/cm2), respectively.

Conclusions: The demonstrated high cytotoxic response after simultaneous exposure of melanoma cells to psoralens and UVA radiation in vitro suggests the usefulness of PUVA therapy to treat melanoma in vivo.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Acknowledgements

This work was supported by the Medical University of Silesia [Grant No. KNW-1-050/K/6/0].

Disclosure statement

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Additional information

Funding

Medical University of Silesia [Grant No. KNW-1-050/K/6/0].

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.